Biotage 과거 수익 실적

OM:BIOT 수익, 비용 및 수입 (SEK Millions )
날짜	수익	수익	G+A 비용	R&D 비용
30 Sep 24	2,117	257	759	179
30 Jun 24	2,077	251	734	182
31 Mar 24	1,981	236	695	174
31 Dec 23	1,862	246	636	159
30 Sep 23	1,603	189	622	140
30 Jun 23	1,554	216	578	125
31 Mar 23	1,541	240	546	112
31 Dec 22	1,566	268	529	109
30 Sep 22	1,524	240	494	107
30 Jun 22	1,428	228	467	98
31 Mar 22	1,337	216	432	96
31 Dec 21	1,232	205	396	91
30 Sep 21	1,188	203	372	80
30 Jun 21	1,145	187	353	76
31 Mar 21	1,096	174	355	73
31 Dec 20	1,092	175	375	72
30 Sep 20	1,083	149	394	76
30 Jun 20	1,103	179	417	79
31 Mar 20	1,131	201	415	79
31 Dec 19	1,101	187	399	79
30 Sep 19	1,047	196	375	77
30 Jun 19	997	173	352	72
31 Mar 19	951	170	339	70
31 Dec 18	911	168	324	66
30 Sep 18	865	175	309	59
30 Jun 18	811	162	292	60
31 Mar 18	771	148	275	56
31 Dec 17	748	139	262	56
30 Sep 17	738	122	262	53
30 Jun 17	728	118	259	52
31 Mar 17	694	105	253	52
31 Dec 16	668	93	245	49
30 Sep 16	657	96	234	52
30 Jun 16	640	87	230	51
31 Mar 16	625	78	224	49
31 Dec 15	611	73	222	50
30 Sep 15	580	83	214	47
30 Jun 15	549	75	204	44
31 Mar 15	521	75	196	43
31 Dec 14	490	65	187	38
30 Sep 14	474	53	182	35
30 Jun 14	459	49	178	34
31 Mar 14	455	46	178	34
31 Dec 13	445	41	177	33

양질의 수익: BIOT 은 높은 수익을 보유하고 있습니다.

이익 마진 증가: BIOT 의 현재 순이익 이익률 (12.1%) 작년보다 높습니다 (11.8%).

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: BIOT 의 수입은 지난 5년 동안 매년 7.3% 씩 증가했습니다.

성장 가속화: 지난 1년간 BIOT 의 수익 증가율( 36% )은 연간 평균( 7.3% 초과합니다. ).

수익 대 산업: 지난 1년간 BIOT 수익 성장( 36% )은 Life Sciences 업계 36% 능가하지 못했습니다. 36%.

Biotage 과거 수익 실적

과거 기준 확인 4/6

주요 정보

최근 과거 실적 업데이트

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Biotage AB (publ) to Report Fiscal Year 2024 Final Results on Apr 03, 2025

Biotage AB (publ) to Report First Half, 2025 Results on Jul 16, 2025

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Weak Statutory Earnings May Not Tell The Whole Story For Biotage (STO:BIOT)

Recent updates

Are Investors Undervaluing Biotage AB (publ) (STO:BIOT) By 48%?

Earnings Miss: Biotage AB (publ) Missed EPS By 15% And Analysts Are Revising Their Forecasts

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Biotage AB (publ) to Report Fiscal Year 2024 Final Results on Apr 03, 2025

Price target decreased by 9.2% to kr173

Biotage AB Appoints Nomination Committee

Investors Interested In Biotage AB (publ)'s (STO:BIOT) Earnings

Biotage AB (publ) to Report First Half, 2025 Results on Jul 16, 2025

Biotage AB Announces Chief Executive Officer Changes, Effective September 16, 2024

Insider recently bought kr575k worth of stock

KKR Reportedly Mulls Options for Stake in Biotage

KKR Reportedly Mulls Options for Stake in Biotage

Biotage AB (publ) Just Missed EPS By 7.7%: Here's What Analysts Think Will Happen Next

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 9.6% to kr190

Are Investors Undervaluing Biotage AB (publ) (STO:BIOT) By 39%?

Price target decreased by 7.1% to kr173

Is Biotage AB (publ) (STO:BIOT) Potentially Undervalued?

Revenue Beat: Biotage AB (publ) Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates

Biotage AB (Publ) Approves a Dividend, Payable on May 3, 2024

Upcoming dividend of kr1.60 per share

Biotage's (STO:BIOT) Dividend Will Be SEK1.60

Biotage AB (publ) Just Beat EPS By 53%: Here's What Analysts Think Will Happen Next

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 7.1% to kr173

Biotage (STO:BIOT) Has Announced A Dividend Of SEK1.60

Biotage (STO:BIOT) Has Announced A Dividend Of SEK1.60

Dividend of kr1.60 announced

Weak Statutory Earnings May Not Tell The Whole Story For Biotage (STO:BIOT)

Subdued Growth No Barrier To Biotage AB (publ) (STO:BIOT) With Shares Advancing 32%

Biotage AB (publ) Just Recorded A 53% EPS Beat: Here's What Analysts Are Forecasting Next

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improves as stock rises 23%

Biotage Appoints Andrew Kellett as CFO

Biotage (STO:BIOT) Has A Pretty Healthy Balance Sheet

Now 23% overvalued after recent price rise

Investors Still Waiting For A Pull Back In Biotage AB (publ) (STO:BIOT)

Now 22% undervalued

Biotage AB (publ) Announces CEO Changes

At kr124, Is It Time To Put Biotage AB (publ) (STO:BIOT) On Your Watch List?

Estimating The Intrinsic Value Of Biotage AB (publ) (STO:BIOT)

Third quarter 2023 earnings: Revenues in line with analyst expectations

Investor sentiment improves as stock rises 27%

Now 20% undervalued after recent price drop

Biotage AB (publ), Annual General Meeting, Apr 25, 2024

Consensus EPS estimates fall by 26%

Biotage AB (Publ) Announces Executive Changes

New minor risk - Insider selling

Insider recently sold kr675k worth of stock

Biotage AB (publ) to Report Q1, 2024 Results on Apr 25, 2024

Second quarter 2023 earnings: Revenues exceed analyst expectations

Does Biotage (STO:BIOT) Have A Healthy Balance Sheet?

Consensus EPS estimates fall by 26%

Price target decreased by 29% to kr180

Now 23% undervalued

New minor risk - Shareholder dilution

An Intrinsic Calculation For Biotage AB (publ) (STO:BIOT) Suggests It's 26% Undervalued

Biotage (STO:BIOT) Ticks All The Boxes When It Comes To Earnings Growth

Investor sentiment improves as stock rises 24%

Director recently bought kr2.0m worth of stock

Upcoming dividend of kr1.60 per share at 1.3% yield

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Biotage's (STO:BIOT) Upcoming Dividend Will Be Larger Than Last Year's

Price target decreased by 12% to kr212

These 4 Measures Indicate That Biotage (STO:BIOT) Is Using Debt Safely

Consensus EPS estimates fall by 17%, revenue upgraded

Is It Too Late To Consider Buying Biotage AB (publ) (STO:BIOT)?

Biotage AB (Publ) Proposes Dividend for 2022

Full year 2022 earnings released: EPS: kr4.06 (vs kr3.14 in FY 2021)